1https://www.avient.com/sites/default/files/2020-09/stat-tech-tri-fold-processing-guide.pdf 2https://www.avient.com/sites/default/files/2020-12/therma-tech-processing-guide.pdf 1Gravi-Tech Processing Guide https://www.avient.com/sites/default/files/2020-10/2020-gravi-tech-processing-guide.pdf

1https://www.avient.com/sites/default/files/2020-09/stat-tech-tri-fold-processing-guide.pdf 2https://www.avient.com/sites/default/files/2020-12/therma-tech-processing-guide.pdf 1Gravi-Tech Processing Guide https://www.avient.com/sites/default/files/2020-10/2020-gravi-tech-processing-guide.pdf

Any action that may be taken at a meeting of the Committee may be taken by written consent so long as the written consent is unanimously approved and filed with the Corporate Secretary. 4 • The Company’s General Counsel and Corporate Secretary will be the management liaison to the Committee

A full copy of Avient’s Code of Conduct is available in over 20 languages and can be found here: Avient’s Position on Human Rights can be found here http://www.avient.com/ https://www.avient.com/company/policies-and-governance-0/code-conduct https://www.avient.com/sites/default/files/2021-07/avient-human-rights-position-statement-updated-july-2021.pdf Page 2 of 3 Training To mitigate against the risk of non-compliance with our policy, Avient requires all associates to complete mandatory Code of Conduct training.

The action of a majority of those present at a meeting at which a quorum is present will be the act of the Committee. 4 Any action that may be taken at a meeting of the Committee may be taken by written consent so long as the written consent is unanimously approved and filed with the Corporate Secretary.

 Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to:  The final amount of charges resulting from the planned North American asset realignment and the Company’s ability to realize anticipated savings and operational benefits from the asset realignment;  Our ability to achieve the strategic and other objectives relating to the acquisition of Spartech Corporation, including any expected synergies;  Our ability to successfully integrate Spartech and achieve the expected results of the acquisition, including, without limitation, the acquisition being accretive;  Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future;  The financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate liquidity) to maintain their credit availability;  The speed and extent of an economic recovery, including the recovery of the housing market;  Our ability to achieve new business gains;  The effect on foreign operations of currency fluctuations, tariffs, and other political, economic and regulatory risks;  Changes in polymer consumption growth rates in the markets where we conduct business;  Changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online;  Fluctuations in raw material prices, quality and supply and in energy prices and supply;  Production outages or material costs associated with scheduled or unscheduled maintenance programs;  Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters;  An inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital reductions, cost reductions, employee productivity goals, and an inability to raise or sustain prices for products or services;  An inability to raise or sustain prices for products or services;  An inability to maintain appropriate relations with unions and employees;  The inability to achieve expected results from our acquisition activities;  Our ability to continue to pay cash dividends;  The amount and timing of repurchases of our common shares, if any; and  Other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation The non-GAAP financial measures include: adjusted EPS, earnings before interest, tax, depreciation and amortization (EBITDA), adjusted EBITDA, net debt, Specialty platform operating income, Specialty platform gross margin percentage, adjusted operating income, return on invested capital, net debt/ EBITDA, and the exclusion of corporate charges in certain calculations.

TAXES Seller's invoices will include value added tax, and such value added tax shall be a separate line item on the invoice. Seller shall not be liable to Buyer for any other taxes or duties of any kind unless specifically and mutually agreed to between the parties. 9.

SEC Filings

En outre, à n’importe quel moment avant la livraison, le vendeur peut répercuter toute augmentation des frais de fret, de transport ou de carburant et/ou des droits, des tarifs ou des taxes qui lui sont imposés dans le cadre de la vente ou de la livraison des produits après avoir accepté la commande. Taxes, frais et droits. L’acheteur remboursera au vendeur l’ensemble des taxes fédérales, étatiques, provinciales, locales et autres (à l’exception des impôts sur le revenu), des taxes d’utilisation et d’accise et des frais, y compris les frais de remise en état de l’environnement, ainsi que les taxes, frais et droits de toute nature que le vendeur doit débourser en lien avec la fabrication et la fourniture des produits, mais uniquement les sommes qui ne sont pas déjà incluses dans le prix indiqué lors de l’entrée en vigueur du présent contrat.

COMPREHENSIVE REGULATORY TESTING AND DOCUMENTATION Raw materials tested to: • ISO 10993-1 and USP , (biological evaluation) • European Pharmacopeia 3.1.3/3.1.5 (polyolefin —materials used for the manufacture of containers) • USP (polyethylene—plastic materials of construction) • ICH Q3D (elemental impurities) We provide Drug Master File (Type III) documentation and other supporting regulatory declarations that are relevant for the application.